<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096590</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000440092</org_study_id>
    <secondary_id>NCI-05-CC-0033</secondary_id>
    <nct_id>NCT00096590</nct_id>
    <nct_alias>NCT00464360</nct_alias>
  </id_info>
  <brief_title>Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery</brief_title>
  <official_title>Evaluation of a Novel Blood Test Hypercoagulability in Surgical Patients With Metastatic Carcinoma: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: A test that detects abnormal blood clotting in patients with cancer may help&#xD;
      doctors plan cancer surgery.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at a new blood test to detect abnormal clotting in&#xD;
      patients with metastatic cancer undergoing surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine whether whole blood thrombin generation assay (WBTGA) detects&#xD;
           hypercoagulability in patients with metastatic carcinoma compared with a healthy control&#xD;
           group.&#xD;
&#xD;
        -  Determine whether results of the WBTGA will change as a result of major surgery&#xD;
           performed on patients with metastatic carcinoma.&#xD;
&#xD;
        -  Establish a reference interval for the WBTGA using healthy controls.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare a battery of plasma components known to affect or reflect coagulant or&#xD;
           fibrinolytic reactions in patients with metastatic carcinoma vs healthy controls.&#xD;
&#xD;
        -  Establish reference intervals for this battery of tests using healthy controls.&#xD;
&#xD;
        -  Determine how major surgery in cancer patients affects this battery of factors.&#xD;
&#xD;
        -  Identify changes in these factors that correlate with changes in the WBTGA.&#xD;
&#xD;
        -  Compare the results of WBTGA tests in patients who develop venous thromboembolism (VTE)&#xD;
           with those who do not.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Blood samples of patients are collected on day -7 and day 1 after surgery.&#xD;
&#xD;
      Blood samples of healthy controls are collected once.&#xD;
&#xD;
      After collection, blood samples are analyzed for hypercoagulability by whole blood thrombin&#xD;
      generation assay. Routine blood tests are performed, as are immunoenzyme techniques for&#xD;
      antigenic tissue plasminogen activator and its inhibitor, thrombin-antithrombin complexes,&#xD;
      tissue factor, factor VIIa, D-dimer, and glycocalicin.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients and 30 healthy controls will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Incidence of hypercoagulability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the results of whole blood thrombin generation assay tests in patients who develop venous thromboembolism with those who do not</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Thromboembolism</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>coagulation study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>physiologic testing</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>study of high risk factors</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Patients meeting the following criteria:&#xD;
&#xD;
               -  Diagnosis of metastatic carcinoma&#xD;
&#xD;
               -  Must be enrolled in 1 of the following surgical protocols:&#xD;
&#xD;
                    -  NCI-99-C-0123&#xD;
&#xD;
                    -  NCI-00-C-0069&#xD;
&#xD;
                    -  NCI-03-C-0085&#xD;
&#xD;
                    -  NCI-03-C-0212&#xD;
&#xD;
          -  Healthy control participant* meeting the following criteria:&#xD;
&#xD;
               -  No anemia or thrombocytopenia&#xD;
&#xD;
               -  No history of venous thromboembolism (deep vein thrombosis, pulmonary emboli)&#xD;
&#xD;
               -  No history of coronary artery disease or stroke&#xD;
&#xD;
               -  No chronic inflammatory disease&#xD;
&#xD;
               -  No diabetes mellitus&#xD;
&#xD;
               -  Have not smoked tobacco within the past 6 months NOTE: * Selected on the basis of&#xD;
                  gender and age to match the patients as they are accrued&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No symptomatic infections or other acute illness within the past 14 days&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 3 days since prior drugs known to inhibit platelet function&#xD;
&#xD;
          -  At least 7 days since prior acetylsalicylic acid&#xD;
&#xD;
          -  No concurrent estrogen contraceptives or hormone replacement therapy&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>McDonald K. Horne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Horne MK 3rd, Merryman PK, Cullinane AM, Nghiem K, Alexander HR. The impact of major surgery on blood coagulation factors and thrombin generation. Am J Hematol. 2007 Sep;82(9):815-20.</citation>
    <PMID>17570509</PMID>
  </results_reference>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>November 11, 2004</study_first_submitted>
  <study_first_submitted_qc>November 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2004</study_first_posted>
  <last_update_submitted>May 9, 2009</last_update_submitted>
  <last_update_submitted_qc>May 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2009</last_update_posted>
  <keyword>thromboembolism</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

